Trial Profile
Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in the Treatment of Acute Pulmonary Thromboembolism (PE).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Fondaparinux sodium (Primary) ; Heparin
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 26 Sep 2009 New trial record